MRI subtypes in Parkinson’s disease across diverse populations and clustering approaches
Abstract Parkinson’s disease (PD) is clinically heterogeneous, which suggests the existence of subtypes; however, there has been no consensus regarding their characteristics. This study included 633 PD individuals across distinct cohorts: unmedicated de novo PD, medicated PD, mild-moderate PD, and a cohort based on diagnostic work-up in clinical practice. Additionally, 233 controls were included. Clustering based on cortical and subcortical gray matter measures was conducted with and without adjusting for global atrophy in the entire PD sample and validated within each cohort. Subtypes were characterized using baseline and longitudinal demographic and clinical data. Unadjusted results identified three clusters showing a gradient of neurodegeneration and symptom severity across the entire sample and the individual cohorts. When adjusting for global atrophy eight clusters were identified in the entire sample, lacking consistency in individual cohorts. This study identified atrophy-based subtypes in PD, emphasizing the significant impact of global atrophy on subtype number, patterns, and interpretation in cross-sectional analyses.
Authors
- Erika Franzén (ORCID: https://orcid.org/0000-0001-5520-544X)
- J‐Sebastian Muehlboeck
- Henrik Sjöström (ORCID: https://orcid.org/0000-0001-7061-6941)
- Bàrbara Segura (ORCID: https://orcid.org/0000-0002-9673-5479)
- Carme Junqué (ORCID: https://orcid.org/0000-0002-6381-3063)
- Daniel Ferreira (ORCID: https://orcid.org/0000-0001-9522-4338)
- Per Svenningsson (ORCID: https://orcid.org/0000-0001-6727-3802)
- Tobias Granberg (ORCID: https://orcid.org/0000-0001-6700-1022)
- Anna Inguanzo (ORCID: https://orcid.org/0000-0003-0879-5875)
- Franziska Albrecht (ORCID: https://orcid.org/0000-0002-5891-445X)
- Konstantinos Poulakis (ORCID: https://orcid.org/0000-0002-6600-8086)
- Eric Westman (ORCID: https://orcid.org/0000-0002-3115-2977)
- Rosaleena Mohanty (ORCID: https://orcid.org/0000-0001-6499-1251)
Institutions
- Karolinska University Hospital (SE)
- Wellcome Centre for Human Neuroimaging (GB)
- King's College London (GB)
- Karolinska Institutet (SE)
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Universidad Fernando Pessoa Canarias (ES)
- Centro de Investigación Biomédica en Red (ES)
- Centre for Palaeogenetics (SE)
- Fundació Clínic per a la Recerca Biomèdica (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- npj Parkinson s Disease
- Published
- 2024-08-16
- DOI
- https://doi.org/10.1038/s41531-024-00759-2
- Citations
- 14
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.17
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Celgene
- Gun och Bertil Stohnes Stiftelse
- Loo och Hans Ostermans Stiftelse för Medicinsk Forskning
- Stiftelsen för Gamla Tjänarinnor
- Parkinson's Foundation
- Neurocrine Biosciences
- Centres de Recerca de Catalunya
- Verily Life Sciences
- Voyager Therapeutics
- Generalitat de Catalunya
- Fondation pour la Recherche Médicale
- Ministerio de Economía y Competitividad
- Svenska Sällskapet för Medicinsk Forskning
- Hjärnfonden
- Karolinska Institutet
- Stiftelsen Olle Engkvist Byggmästare
- Stockholms Läns Landsting
- Vetenskapsrådet
- Stiftelsen Lars Hiertas Minne
- Ministerio de Ciencia e Innovación
- Universitat de Barcelona
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
- Alzheimerfonden
- Servier
- H. Lundbeck A/S
- Sun Pharma
- Genentech
- Allergan
- Parkinsonfonden
- Avid Radiopharmaceuticals
- Agencia Estatal de Investigación
- Center for Innovative Medicine